During concurrent use , patients should contact their healthcare provider if they experience: Symptoms of hypoglycemia (shakiness, sweating, confusion, rapid heartbeat) Severe, persistent abdominal pain (often radiating to the back) with or without vomitingthis could indicate pancreatitis, a serious adverse effect associated with GLP-1 receptor agonists requiring urgent medical evaluation Unexplained fatigue, jaundice, or abdominal pain (potential liver concerns) Worsening gastrointestinal symptoms beyond typical semaglutide side effects New or unusual symptoms that may represent an adverse reaction Patients taking oral medications with a narrow therapeutic index should discuss timing and monitoring with their healthcare provider, as semaglutide's effect on gastric emptying may affect absorption
Think of them as "trial doses" that allow both you and your doctor to observe any adverse reactions before committing to higher doses
However, there is currently no research proving these benefits
We focus on the overall patient experience by providing exceptional, individualized and easily accessible care using value-based care strategies
Reddys Laboratories has launched its semaglutide injection, marketed as Obeda, marking its entry into the GLP-1 receptor agonist therapy segment for the management of type 2 diabetes in India
The magnitude differs: A 2025 NYU Langone study found surgical patients lost 58 pounds after two years versus 12 pounds for GLP-1 prescription patients
